In a filing, Olema Pharmaceuticals Inc revealed its Director Harmon Cyrus unloaded Company’s shares for reported $0.22 million on Mar 28 ’24. In the deal valued at $10.97 per share,20,000 shares were sold. As a result of this transaction, Harmon Cyrus now holds 826,283 shares worth roughly $8.16 million.
Then, Harmon Cyrus sold 25,000 shares, generating $310,309 in total proceeds. Upon selling the shares at $12.41, the Director now owns 846,283 shares.
Before that, Harmon Cyrus sold 5,000 shares. Olema Pharmaceuticals Inc shares valued at $77,800 were divested by the Director at a price of $15.56 per share. As a result of the transaction, Harmon Cyrus now holds 871,283 shares, worth roughly $8.6 million.
Goldman initiated its Olema Pharmaceuticals Inc [OLMA] rating to a Buy in a research note published on April 02, 2024; the price target was $24. A number of analysts have revised their coverage, including Citigroup’s analysts, who began to cover the stock in late January with a ‘”a Buy”‘ rating. Oppenheimer began covering OLMA with “an Outperform” recommendation on July 21, 2023. CapitalOne started covering the stock on May 05, 2023. It rated OLMA as “an Overweight”.
Price Performance Review of OLMA
On Monday, Olema Pharmaceuticals Inc [NASDAQ:OLMA] saw its stock fall -0.60% to $9.87. Over the last five days, the stock has lost -9.03%. Olema Pharmaceuticals Inc shares have fallen nearly -29.65% since the year began. Nevertheless, the stocks have risen 139.56% over the past one year. While a 52-week high of $17.79 was reached on 02/13/24, a 52-week low of $3.85 was recorded on 04/19/24. SMA at 50 days reached $12.39, while 200 days put it at $12.11. A total of 0.68 million shares were traded, compared to the trading of 0.74 million shares in the previous session.
Levels Of Support And Resistance For OLMA Stock
The 24-hour chart illustrates a support level at 9.71, which if violated will result in even more drops to 9.54. On the upside, there is a resistance level at 10.09. A further resistance level may holdings at 10.30. The Relative Strength Index (RSI) on the 14-day chart is 34.91, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.85, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 78.15%. Stochastics %K at 17.41% indicates the stock is a buying.
The most recent change occurred on February 22, 2023 when Credit Suisse began covering the stock and recommended ‘”an Outperform”‘ rating along with a $12 price target.
